Autoimmune Cytopenias

Advances in understanding of the pathophysiology of immune thrombocytopenia (ITP) have led to the development of several novel therapies for patients with this blood disorder. The author reviews current therapies for ITP, including monoclonal antibodies that reduce platelet destruction by targeting CD38, CD40, the immunoproteasome, and the neonatal Fc receptor; therapies that target the phagocytic system; complement inhibitors; and inhibitors of platelet desialylation.